Valneva SE (VALN) Net Cash Flow (2021 - 2026)
Valneva SE's (VALN) quarterly Net Cash Flow came in at -$43317.6 in Q1 2026, up 99.53% year-on-year from -$21710.2 in Q1 2025, and up 99.85% quarter-over-quarter from -$28.7 million in Q4 2025.
Valneva SE (VALN) Net Cash Flow (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Net Cash Flow across 6 years of filings, most recently posting -$43317.6 for Q1 2026.
- Net Cash Flow for Q1 2026 came in at -$43317.6, up 99.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$50.9 million (down 115.26% YoY), and the FY2025 annual result was -$61.7 million, down 243.03% from the prior year.
- Net Cash Flow came in at -$43317.6 for Q1 2026 at Valneva SE, up from -$28.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $88.6 billion in Q3 2023 to a low of -$88.8 billion in Q2 2023.
- The 5-year median for Net Cash Flow is -$9.1 million (2025), against an average of $4.5 million.
- Peak annual rise in Net Cash Flow reached 111539.33% in 2023, while the deepest fall reached 333905.54% in 2023.
- Valneva SE's Net Cash Flow stood at $30.8 million in 2022, then plunged by 254.04% to -$47.4 million in 2023, then soared by 118.19% to $8.6 million in 2024, then tumbled by 432.74% to -$28.7 million in 2025, then surged by 99.85% to -$43317.6 in 2026.
- The last three Net Cash Flow figures came in at -$43317.6 (Q1 2026), -$28.7 million (Q4 2025), and -$18.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 664,983.53 |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -43,317.59 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43,317.59 |
| Mar 31, 2026 | -43,317.59 |
| Dec 31, 2025 | -28.68 Mn |
| Dec 31, 2025 | -28.68 Mn |
| Sep 30, 2025 | -18.41 Mn |
| Sep 30, 2025 | -18.41 Mn |
| Jun 30, 2025 | -3.75 Mn |
| Jun 30, 2025 | -3.75 Mn |
| Mar 31, 2025 | -9.15 Mn |
| Mar 31, 2025 | -9.15 Mn |
| Dec 31, 2024 | 8.62 Mn |
| Dec 31, 2024 | 8.62 Mn |
| Sep 30, 2024 | 18.23 Bn |
| Sep 30, 2024 | 18.23 Bn |
| Jun 30, 2024 | -17.90 Bn |
| Jun 30, 2024 | -17.90 Bn |
| Mar 31, 2024 | 55.35 Mn |
| Mar 31, 2024 | 55.35 Mn |
| Dec 31, 2023 | -47.39 Mn |
| Dec 31, 2023 | -47.39 Mn |